Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis

References Papers of special note have been highlighted as:• of interest•• of considerable interest

• Australian Institute of Health and Welfare. 2004 National Drug Strategy Household Survey – first results. AIHW Cat. No. PHE 57. AIHW (Drug Statistics Series No. 13), Canberra, Australia (2005).
   Google Scholar
• Anthony JC, Warner L, Kessler R. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp. Clin. Psychopharm. 2, 244–268 (1994).
   Web of Science ®Google Scholar
• Intergovernmental Committee on Drugs and the Australian National Council on Drugs. The national drug strategy: Australia’s integrated framework 2004–2009. Commonwealth of Australia, Canberra, Australia (2004).
   Google Scholar
• Mattick RP, Digiusto E, Doran CM et al. National evaluation of pharmacotherapies for opioid dependence (NEPOD). Commonwealth Department of Health and Ageing, Canberra, Australia (2001).
   Google Scholar
• Marsh K, Joe G, Simpson D, Lehman W. Treatment history. In: Opioid Addiction and Treatment: A 12 year Follow-up. Simpson D, Sells S (Eds), Robert E Krieger Publishing Company, FL, USA (1990).
   Google Scholar
• Ward J, Mattick RP, Hall W. Assessment for opioid replacement therapy. In: Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Ward J, Mattick RP, Hall W (Eds), Harwood Academic Publishers, The Netherlands, 177–203 (1998).
   Google Scholar
• Mattick RP, Ali R, White J, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance treatment: a randomised double-blind trial with 405 opioid dependant patients. Addiction 98, 441–452 (2003)
   PubMed Web of Science ®Google Scholar
• Gerstein DR, Harwood HJ. Treating drug problems (Vol 1). In: A Study of Effectiveness and Financing of Pubic and Private Drug Treatment Systems. Institute of Medicine, National Academy Press, WA, USA (1990).
   Google Scholar
• Oliveto A, Korsten T. Buprenorphine. In: New Treatments for Opioid Dependence. Stine S, Bentler PM (Eds.). Guilford Press, NY, USA (1997).
   Google Scholar
• Ward J, Mattick RP, Hall W. Methadone maintenance treatment and other opioid replacement therapies. Harwood Press, London, UK (1998).
   Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. (Cochrane Review). Cochrane Database Syst. Rev. 3 (2005).
   Google Scholar
• Gibson A, Doran C, Bell J, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings. Med. J. Aust. 179, 38–42 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effect at high doses. Clin. Pharmacol. Ther. 55, 569–580 (1994).
   PubMed Web of Science ®Google Scholar
• Comer SD, Collins ED, Fischman MW. Intravenous buprenorphine self-administration by detoxified heroin abusers. J. Pharmacol. Exp. Ther. 301, 266–276 (2003).
   Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04–3939. Substance Abuse and Mental Health Services Administration, MD, USA (2004).
   Google Scholar
• Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone coadministration in opiate-dependent patients stabilised on sublingual buprenorphine. Drug Alcohol Depend. 61, 85–94 (2000).
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Yu E, MacFadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilised opioid addicts. Drug Alcohol Depend. 50, 1–8 (1998).
   PubMed Web of Science ®Google Scholar
• Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 154, 230–242 (2001).
   PubMed Web of Science ®Google Scholar
• Chiang CN, Hawkes RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 70, S39–S47 (2003).
   PubMed Web of Science ®Google Scholar
• Fischer G, Gombas W, Eder H et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94, 1337–1347 (1999).
   PubMed Web of Science ®Google Scholar
• Petitjean S, Stohler R, Deglon JJ et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 62, 97–104 (2001).
   PubMed Web of Science ®Google Scholar
• Commonwealth of Australia. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners, Australian Government Publishing Service, Canberra, Australia (2005).
   Google Scholar
• Doran CM, Holmes J, Ladewig D, Ling W. Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Add. Rel. Clin. Probl. 7, 7–18 (2005).
   Google Scholar
• Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levo-alpha-methadyl-acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 343, 1290–1297 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson RE, Cone EJ, Henningfield JE, Fudala PJ. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin. Pharmacol. Ther. 46, 335–343 (1989).
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S et al. Buprenorphine/naloxone collaborative study group, office based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 349, 949–958 (2003).
   PubMed Web of Science ®Google Scholar
• Gerstein DR, Johnson RA, Harwood HJ, Fountain D, Suter N, Malloy K. Evaluating recovery services: the California drug and alcohol treatment system (CALDATA). California Department of Alcohol and Drug Programs, CA, USA (1994).
   Google Scholar
• Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost–effectiveness analysis. Drug Alcohol Depend. 71, 295–302 (2003).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. American Psychiatric Association, WA, USA (1994).
   Google Scholar
• Commonwealth Department of Health and Family Services. Medicare benefits schedule, Australian Government Publishing Service, Canberra (2001).
   Google Scholar
• Lintzeris N, Clark N, Muhlhiesen P et al. National Clinical Guidelines and Procedures for the use of Buprenorphine in the Treatment of Heroin Dependence. Commonwealth of Australia, Canberra (2001).
   Google Scholar
• SPSS Institute, Inc. Statistical packages for the social sciences. Prentice Hall, IL, USA (2004)
   Google Scholar
• Palisade Corporation. @RISK VBA Macro Language Risk Analysis and Simulation Add-In for Microsoft® Excel Version 4.5. Palisade Corporation, NY, USA (2004).
   Google Scholar
• Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analyses and presentation of uncertainty in cost–effectiveness studies. Ann. Rev. Pub. Health 23, 377–401 (2002).
   PubMed Web of Science ®Google Scholar